MAPT and dementia: Patients treated with AN-1792 [5, 14, 21, 22] similarly had mild-to-moderate AD prior to immunization and all patients progressed to moderate-to-severe dementia with Braak stage V/VI neurofibrillary degeneration despite evidence of plaque reduction and lower NP-Tau and NTs [5, 14, 22].